MVP Act

This bill creates official rules that let drug companies set different prices for medicines in the Medicaid Drug Rebate Program based on how well those medicines actually work for patients, which is called "value-based purchasing." It also requires a government study on how these pricing arrangements affect federal health care programs and tells the Centers for Medicare & Medicaid Services to provide guidance to state Medicaid programs on using these arrangements for drugs given to patients in hospitals. The bill also says that drug sales made under these special pricing arrangements don't have to be counted when figuring out the average sales price used for certain Medicare payments, as long as the drug company follows the new reporting rules.

Your Vote